BibTex format
@article{Wedzicha:2017:10.2147/COPD.S125058,
author = {Wedzicha, JA and Zhong, N and Ichinose, M and Humphries, M and Fogel, R and Thach, C and Patalano, F and Banerji, D},
doi = {10.2147/COPD.S125058},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
pages = {339--349},
title = {Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study},
url = {http://dx.doi.org/10.2147/COPD.S125058},
volume = {12},
year = {2017}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Background: The FLAME study demonstrated that indacaterol/glycopyrronium (IND/GLY),the fixed-dose combination of a long-acting β2-agonist (LABA, IND) and a long-acting muscarinicantagonist (LAMA, GLY), was superior to salmeterol/fluticasone combination (SFC)in preventing exacerbations in COPD patients with a high risk of exacerbations. In this study,we report a prespecified analysis of the efficacy and safety of IND/GLY versus SFC in Asianpatients from the FLAME study.Patients and methods: Patients from Asian centers with moderate-to-very severe COPDand $1 exacerbation in the previous year from the 52-week, randomized FLAME study wereincluded. IND/GLY was compared versus SFC for effects on exacerbations, lung function(forced expiratory volume in 1 second [FEV1] and forced vital capacity [FVC]), health status(St George’s Respiratory Questionnaire [SGRQ]), rescue medication use, and safety.Results: A total of 510 Asian patients (IND/GLY, n=250 or SFC, n=260) were included.Compared to the overall FLAME population, the Asian cohort had more males, a shorter durationof COPD, fewer patients using inhaled corticosteroid (ICS) at screening, fewer currentsmokers, and more patients with very severe COPD. IND/GLY significantly reduced the rate ofmoderate/severe exacerbations (rate ratio: 0.75; 95% confidence interval: 0.58–0.97; P=0.027)and prolonged time to first moderate/severe exacerbation versus SFC (hazard ratio: 0.77; 95%confidence interval: 0.59–1.01; P=0.055). Predose trough FEV1 and FVC significantly improvedin Asian patients (P,0.001). IND/GLY improved SGRQ for COPD (SGRQ-C score; P=0.006)and reduced rescue medication use (P=0.058) at week 52. Pneumonia incidence was 3.6% withIND/GLY and 7.7% with SFC (P=0.046).Conclusion: In exacerbating Asian COPD patients, IND/GLY was more effective than SFC
AU - Wedzicha,JA
AU - Zhong,N
AU - Ichinose,M
AU - Humphries,M
AU - Fogel,R
AU - Thach,C
AU - Patalano,F
AU - Banerji,D
DO - 10.2147/COPD.S125058
EP - 349
PY - 2017///
SN - 1176-9106
SP - 339
TI - Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
T2 - International Journal of Chronic Obstructive Pulmonary Disease
UR - http://dx.doi.org/10.2147/COPD.S125058
VL - 12
ER -